Lisa’s research is focused on the identification of novel cancer drug combinations in cancer types with an unmet clinical need, such as KRAS-mutant colorectal and triple-negative breast cancers. This will be acheived using a next generation dual guide CRISPR/Cas9 system to idenitify novel genetic interactions across multiple cancer cell lines.